NASDAQ:AIMT Aimmune Therapeutics (AIMT) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$34.49▼$34.4950-Day Range$34.30▼$34.5952-Week Range$10.09▼$37.00VolumeN/AAverage Volume1.71 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Aimmune Therapeutics (NASDAQ:AIMT) StockAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Read More Receive AIMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AIMT Stock News HeadlinesJune 30, 2022 | finance.yahoo.comAimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022November 12, 2021 | financialpost.comAimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital MeetingMay 30, 2023 | Edge On The Street (Ad)The Largest Ever Technology Wave Is Coming!This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.October 26, 2021 | finance.yahoo.comAimmune Closes Enrolment in Phase III Peanut Allergy StudyAugust 4, 2021 | ca.finance.yahoo.comAimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut AllergyJuly 9, 2021 | yahoo.comAimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021June 18, 2021 | investing.comAimmune Therapeutics Inc (AIMT)February 25, 2021 | finance.yahoo.comAimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 YearsMay 30, 2023 | Edge On The Street (Ad)The Largest Ever Technology Wave Is Coming!This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.February 11, 2021 | insidermonkey.comBillionaire Paul Tudor Jones’ Top 5 Stock PicksDecember 22, 2020 | apnews.comEuropean Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EUNovember 20, 2020 | apnews.comAimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action ...November 19, 2020 | benzinga.comAimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law FirmOctober 15, 2020 | sg.finance.yahoo.comAIMT Jan 2023 20.000 putOctober 15, 2020 | sg.finance.yahoo.comAIMT Dec 2020 20.000 callOctober 15, 2020 | markets.businessinsider.comMonteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of CaliforniaOctober 15, 2020 | sg.finance.yahoo.comAIMT Jan 2023 22.500 putOctober 15, 2020 | sg.finance.yahoo.comAIMT Nov 2020 40.000 putOctober 14, 2020 | nasdaq.comNestle Completes Acquisition Of Aimmune Therapeutics - Quick FactsOctober 13, 2020 | nasdaq.comNestle Says About 84% Aimmune Shares TenderedOctober 13, 2020 | prnewswire.comNestlé announces results of tender offer for Aimmune Therapeutics, Inc.September 29, 2020 | finance.yahoo.comAimmune Therapeutics (AIMT) Q2 2020 Earnings Call TranscriptSeptember 22, 2020 | stockhouse.comSHAREHOLDER ALERT: Halper Sadeh LLP Is Investigating the Following Companies; Shareholders are Encouraged to Contact the Firm - PTI, BYFC, RST, AIMTSeptember 22, 2020 | finance.yahoo.comKaskela Law LLC Announces Investigation of Aimmune Therapeutics, Inc. (AIMT) and Encourages Stockholders to Contact the FirmSeptember 18, 2020 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMTSeptember 14, 2020 | nasdaq.comNestlé Initiates Tender Offer To Buy Aimmune Therapeutics For $34.50/ Share In CashSeptember 14, 2020 | seekingalpha.comNestle initiates tender offer for Aimmune TherapeuticsSee More Headlines Receive AIMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AIMT Company Calendar Last Earnings7/30/2020Today5/29/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AIMT CUSIPN/A CIK1631650 Webwww.aimmune.com Phone650-614-5220FaxN/AEmployees228Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-248,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-164.99% Return on Assets-89.50% Debt Debt-to-Equity Ratio0.73 Current Ratio7.53 Quick Ratio7.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.66 per share Price / Book20.78Miscellaneous Outstanding Shares65,450,000Free FloatN/AMarket Cap$2.26 billion OptionableOptionable Beta1.76 Key ExecutivesDr. Jayson Donald Alexander Dallas (Age 51)Pres, CEO & Director Mr. Eric H. Bjerkholt (Age 59)Chief Financial Officer Mr. Douglas T. Sheehy (Age 52)Gen. Counsel & Sec. Dr. Stephen George Dilly (Age 59)Special Advisor Dr. Daniel C. Adelman (Age 62)Chief Medical Officer Key CompetitorsViking TherapeuticsNASDAQ:VKTXHUTCHMEDNASDAQ:HCMAkero TherapeuticsNASDAQ:AKRONuvalentNASDAQ:NUVLBridgeBio PharmaNASDAQ:BBIOView All Competitors AIMT Stock - Frequently Asked Questions How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics, Inc. (NASDAQ:AIMT) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, meeting the consensus estimate of ($1.06). What other stocks do shareholders of Aimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Block (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU). When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO. What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $34.49. How much money does Aimmune Therapeutics make? Aimmune Therapeutics (NASDAQ:AIMT) has a market capitalization of $2.26 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. How many employees does Aimmune Therapeutics have? The company employs 228 workers across the globe. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The official website for the company is www.aimmune.com. The biotechnology company can be reached via phone at 650-614-5220 or via email at dsheel@aimmune.com. This page (NASDAQ:AIMT) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aimmune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.